Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis

Launched by INSTITUT PASTEUR · Oct 27, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how certain medications, known as anti-IL-23 biologics, work in patients with psoriasis, a skin condition that causes red, flaky patches. The goal is to learn more about how these treatments affect the body at a cellular level. The study is taking place at the Cochin Hospital's dermatology department and is currently looking for participants.

To join the trial, you must be an adult over 18 years old with a diagnosis of psoriasis and need systemic treatment (which means treatment that affects the whole body). You also must not have previously received biological therapies. If you meet these criteria, you may be eligible to participate. As a participant, you can expect to receive treatment, undergo assessments, and contribute to important research that could help improve psoriasis treatments in the future. It's important to note that there are specific conditions that would exclude someone from participating, such as being pregnant, having a weakened immune system, or having received certain treatments recently.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• All patients:
• • Adults (\>18 years)
• • Presenting with cutaneous psoriasis
• • Patients have signed an informed consent
• • Beneficiary of the health insurance, except for the AME Only for patients of Group 1
• • Patients require systemic treatment for psoriasis
• • Patients are naïve to biological therapies
• Only for patients of Group 2:
• • Patients requiring treatment with anti-IL-23 biologics (guselkumab, risankizumab, tildrakizumab) upon referent physician's decision.
• • Patients are naïve to biological therapies or have received only one biologic, with a "wash-out" period of at least 4 months
• Non inclusion Criteria:
• For all :
• • Patient is minor
• • Patient is pregnant or breastfeeding
• • Patient is immunocompromised
• • Patient is under legal protection, curatorship, guardianship
• • Patient refuses consent
• • Patient is unable to comply with study requirements for geographic, social or psychiatric reason.
• • Beneficiary of the AME Only for patients of Group 1
• • Patient has received biologics Only for patients of Group 2
• • Patient has a contraindication to the chosen biotherapy
• • Patient has received biologics within the last 4 months
• • Patient has been treated with 2 or more biologics
• • Patient has already received an anti-IL-23 biologic